ArticleScientific reports2026
Post-Chornobyl thyroid papillary carcinomas display distinct past
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Most previous studies aimed to establish etiological signatures of thyroid tumors compared sporadic papillary thyroid carcinomas (sPTC) and PTC that develop in individuals exposed to ionizing radiation during childhood. However, such approaches may lead to a biased signature combining exposure markers independent of the carcinogenic process and markers of radiation-induced carcinogenesis. We analyzed the miRNome (Affymetrix) and transcriptome (RNA sequencing) of a series of normal thyroid tissues and PTC from Ukrainian individuals contaminated with iodine-131 released by the Chornobyl Nuclear Power Plant in 1986 at high (> 0.5 Gy; N = 9) or low (< 50 mGy; N = 12) thyroid radiation doses, and from unexposed Ukrainian individuals (N = 28). First, the six sample groups were analyzed jointly using partial least squares discriminant analysis (sPLS-DA) to assess whether normal tissues and PTC shared common multi-omic signatures associated with exposure history, independent of carcinogenesis. Next, we applied a multiblock sPLS-DA (DIABLO) to isolate markers associated with exposure in the three normal tissue groups. Then, using the remaining miR and genes from the datasets not associated with exposure, we searched for a multi-omics signature associated with a difference in the carcinogenic process. sPLS-DA analysis of the six sample groups showed that normal tissues and PTC from exposed individuals shared a common multi-omics signature (58 miR/snoRNA, 50 genes) compared to unexposed samples. Our DIABLO analysis identified 44 miR/snoRNA and 45 genes exposure signatures distinguishing exposed from unexposed normal tissues. These signatures, when applied to PTC groups, supported that PTC developed after radiation exposure exibited exposure markers independent of any carcinogenic process. In addition to this exposure signature, we identified 39 miR/snoRNA and 64 genes signatures that identified the PTC developed after radiation exposure which deviated significantly from the sPTC profile. Normal tissues and PTC from exposed individuals exhibit a common molecular long-term memory of exposure history. Furthermore, PTC developed after radiation exposure display dose-dependent molecular specificities compared to sPTC. As PTC associated with low doses are mainly subclinical sPTC revealed by screening in the post-Chornobyl population, the proposed multi-omic signature could be attributable to sPTC developed in an exposed thyroid gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.